Versameb develops next‑generation RNA therapeutics by engineering optimized RNA sequences and proprietary delivery vectors such as lipid nanoparticles and polymeric carriers. Their platform improves cellular uptake, stability, and target specificity, enabling pharmaceutical and biotech partners to accelerate the development of effective RNA‑based treatments across multiple disease areas.
Funding
$10M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current RNA‑based medicines often suffer from limited delivery efficiency, instability in the bloodstream, and off‑target effects, which restrict their therapeutic potential and increase development costs.
Solution
Versameb focuses on creating the next generation of RNA therapeutics by engineering novel RNA molecules and delivery platforms that improve cellular uptake, enhance stability, and increase target specificity. Their approach combines advanced sequence design with proprietary lipid or polymer carriers to protect RNA payloads and facilitate precise tissue targeting. The platform enables rapid development of treatments across a range of disease areas, aiming to translate improved molecular performance into more effective clinical outcomes.
Target Audience
Primary customers are pharmaceutical and biotech companies seeking advanced RNA therapeutic candidates and delivery solutions for clinical development.
Features
- Optimized RNA sequence design for increased potency and reduced immunogenicity
- Proprietary delivery vectors (e.g., lipid nanoparticles or polymeric carriers) that enhance cellular uptake and protect RNA from degradation
- Modular platform allowing rapid adaptation to different therapeutic targets and disease indications
- Integrated manufacturing pipeline to ensure scalable, GMP‑compliant production of RNA therapeutics
- Preclinical validation framework that assesses biodistribution, efficacy, and safety in relevant models